Loading
Trouble with memory, concentration and word-finding after chemotherapy is real and measurable, and what a person reports and what a test shows often do not match. Cognitive rehabilitation is the approach with the best trial evidence, exercise helps on some measures and not others, and every drug tried so far has failed, including a large trial of donepezil.
What is reported. In a prospective study of 581 women with breast cancer and 364 age-matched controls, a clinically significant decline in self-reported cognitive function was reported by 45.2 per cent of patients against 10.4 per cent of controls from before to after chemotherapy, and 36.5 against 13.6 per cent at six months.
What is measured. In the same cohort, objective testing showed patients declining from before chemotherapy to six months afterwards while controls did not, across multiple domains. A smaller study with full neuropsychological testing found cognitive dysfunction in 21 per cent before chemotherapy, decline in 65 per cent during it, and decline in 61 per cent at long-term evaluation, of whom 29 per cent had a new, delayed decline that had not been present earlier.
The mismatch between the two is the finding most worth telling a reader, because it is usually experienced as being disbelieved. A systematic review of 101 studies found that 31 showed no association between self-reported symptoms and neuropsychological results while 14 found one, often confined to limited domains. The authors describe "consistently absent or weak association with neuropsychological test scores". A normal test does not mean the difficulty is imagined; it means the test is measuring something else, usually in a quiet room with no competing demands.
What helps. Cognitive rehabilitation has the best evidence. A web-based programme in 242 survivors significantly improved self-reported cognitive function at the end of the programme and at six months, although "neuropsychological results were not significantly different between the groups". A videoconference-delivered cognitive behavioural programme in 47 breast cancer survivors improved both perceived impairment and measured processing speed against supportive therapy. A network meta-analysis of 31 trials in 2,769 participants found small effects on subjective function and medium effects on total objective cognitive function, attention, executive function and learning and memory.
Exercise is mixed and should be described as mixed. A meta-analysis of 11 trials in 890 breast cancer survivors found significant effects on attention and working memory and on perceived cognitive ability, but the largest single trial, in 253 survivors, found no difference from a health and wellness comparison on either primary outcome, with improvement only in secondary measures of attention and memory.
Drugs. Donepezil was tested properly: 276 breast cancer survivors across 87 practices, and at 24 weeks "treatment groups did not differ", with no significant difference at any timepoint on any domain. Methylphenidate given alongside adjuvant chemotherapy showed no difference on cognition or fatigue. The modafinil result often quoted for cognition came from a secondary analysis inside a fatigue trial using an open-label run-in and randomised withdrawal of responders, which is not evidence that it treats this. Memantine is a separate question belonging to brain radiotherapy rather than chemotherapy, and there it does have randomised support alongside hippocampal avoidance.
What comes back, and when: partial, and mostly in the first year, with a minority developing a delayed decline instead. There is no drug that speeds it. Practical compensation, which is what cognitive rehabilitation teaches, is what the evidence supports, alongside treating the things that make it worse: fatigue, poor sleep, anxiety, pain, anaemia and an untreated thyroid.
Chemotherapy, hormone withdrawal, inflammation, anaemia and disturbed sleep act together on frontal and hippocampal networks, which is why processing speed, working memory and executive function are the domains most affected. Standard neuropsychological tests measure peak performance in optimal conditions, while patients notice failures of divided attention in noisy, demanding settings, which is a plausible reason the two diverge.
Query for this technology: (TITLE:"Thinking and memory after cancer treatment: what is measurable, and what helps" OR ABSTRACT:"Thinking and memory after cancer treatment: what is measurable, and what helps") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Thinking and memory after cancer treatment: what is measurable, and what helps, not a curated reading list.
Shares The exercise prescription after cancer: the dose the guidelines state, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares Cognitive behavioural therapy for fatigue and distress, Testicular germ cell tumours, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship.
Shares The exercise prescription after cancer: the dose the guidelines state, Testicular germ cell tumours, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship.
Shares Mindfulness-based stress reduction and cognitive therapy, Cognitive behavioural therapy for fatigue and distress, Late effects and survivorship toxicity, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Toxicity and quality of life are undervalued, Triple-negative breast cancer (TNBC) and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.